MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from April 17 – 18, 2024.
Details of the fireside chat are as follows:
Date: Wednesday, April 17, 2024
Time: 10 a.m. ET
Location: Presentation Track 1
Webcast: Available in the Events section of Ocugen website
During the fireside chat and one-on-one sessions, Dr. Musunuri will showcase the Company's recent business and clinical development progress including FDA clearance to initiate a Phase 3 clinical trial for OCU400—a modifier gene therapy for patients battling retinitis pigmentosa (RP). OCU400 is the first gene therapy to enter a late-stage trial with a broad RP indication.
A live webcast of the fireside chat will be available in the Events section of the Company's website and as part of a complete catalog of presentations available on Channelchek—the investor portal ...